Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 17/20 | 0.66 |
| ▸ | PRKDC | P78527 | 5/20 | 0.62 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.60 |
| ▸ | PRKCA | P17252 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.55 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3460707 | 0.83 | ALDH1A1 (0.58) | ATRPRKDCATM | |
| SCHEMBL3460080 | 0.82 | TYRO3 (0.60) | ATRTYRO3 | |
| SCHEMBL3461372 | 0.82 | ATR (0.74) | ATRPRKDCATMCYP3A4 | |
| SCHEMBL3461075 | 0.81 | ATR (0.66) | ATRPRKDCATMCYP3A4 | |
| SCHEMBL6711860 | 0.81 | ATR (0.66) | ATRPRKDCATMCYP3A4 | |
| SCHEMBL3460599 | 0.81 | ATR (0.73) | ATRPRKDCTYRO3PRKCAGSK3B | |
| SCHEMBL3042863 | 0.80 | ATR (1.00) | ATRPRKDCATM | |
| SCHEMBL3460865 | 0.80 | TYRO3 (0.66) | ATRTYRO3 | |
| SCHEMBL3593544 | 0.79 | ATR (0.63) | ATRPRKDCATMCYP3A4 | |
| SCHEMBL3462067 | 0.79 | ATR (0.63) | ATRPRKDCATMCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | ATR 556/4885PRKDC 124/4885TYRO3 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.